Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UBS AG filings for WUCT document foreign private issuer reporting and securities-offering disclosures for the ETRACS Whitney US Critical Technologies ETN. The record includes Form 6-K reports, Form 20-F references, IFRS consolidated financial information, capitalization disclosures, and debt and equity presentation for UBS AG and its subsidiaries.
Registration-related filings also incorporate Form F-3 materials and legal opinion exhibits for UBS AG securities offerings. These disclosures address the issuer's reporting framework, capital structure, funding from UBS Group AG, and the formal documentation supporting registered securities.
UBS AG London Branch plans to issue Contingent Income Auto-Callable Securities maturing on or about 30 June 2028 that are linked to the common stock of Meta Platforms, Inc. (META). Each security has a $1,000 stated principal amount and is expected to price on 27 June 2025 and settle on 2 July 2025. Holders may receive quarterly contingent coupons of $27.00 (10.80% p.a.) provided META’s closing price on the relevant observation date is at or above the 60% downside threshold. If on any quarterly determination date (other than the final one) META closes at or above the 100% call threshold, the notes are automatically redeemed at par plus the coupon.
At maturity, investors receive: (i) par plus the final coupon if META is at or above the downside threshold; or (ii) a cash value equal to META’s final price multiplied by the exchange ratio if the downside threshold is breached, exposing investors to losses of up to 100% of principal. The securities do not participate in any upside above par, are unsecured, unsubordinated obligations of UBS and will not be listed on any exchange. Estimated initial value is expected between $934.70 and $964.70, reflecting embedded fees (2.25% selling concession) and dealer margins.
The preliminary prospectus highlights multiple risks: credit exposure to UBS, limited or no secondary market, potential early redemption, price volatility of a single equity, and uncertain U.S. tax treatment. Investors should review the complete risk factors in the preliminary pricing supplement before purchasing.